trial
as of 2026-07-01Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
NCTId NCT06253546
at a glance
Phase 1 · Completed
Enrollment 24 (actual)
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Primary completion 2025-06-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2024-03-28
Primary completion
2025-06-12
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
Investigators
1
Teva Medical Expert, MDStudy Director
Sites
6 total
Beijing, ChinaBeijing, ChinaGuangzhou, ChinaShanghai, ChinaWuhan, ChinaXi'an, China
Facts & assertions
4 sourced
Enrollment
24
Phase
PHASE1
Primary Completion Date
2025-06-12
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
indication
indication
investigator
person